BACKGROUND: Recent studies found use of anticholinergic medications to be associated with greater performance decrements in older persons who carry an ε4 allele of the apolipoprotein E (APOE) gene than in those carrying only ε2 or ε3 alleles. OBJECTIVES: The present study examined whether the apparently greater behavioral toxicity of anticholinergic drugs in ε4 carriers may result from an increased risk of cerebrovascular disease, which is more common in ε4 carriers. METHODS: Cross-sectional data were available from 240 elderly community volunteers who had participated in 2 different studies of the cognitive and motor effects of normal aging. As part of these studies, information was gathered on subjects' use of anticholinergic medications (based on an inventory of medications taken within 24 hours of testing), risk of cerebrovascular disease (Framingham Stroke Risk Profile), and APOE genotype. Performance data were also available from measures of general cognitive status (Mini-Mental State Examination), executive function (Trail Making Test), mood (Geriatric Depression Scale), sleep (Pittsburgh Sleep Quality Index), and walking speed. Logistic and linear regression models were used to examine how outcomes differed between genotypes and drug use, independent of the risk of cerebrovascular disease. RESULTS: In persons with a non-ε4 genotype, anticholinergic medication use did not significantly affect any of the behavioral measures. By contrast, among ε4 carriers, those taking anticholinergic drugs performed significantly worse than did those not taking such drugs on tests of general cognitive status, executive function, mood, and sleep. Adjusting for participants' stroke risk had a minimal effect on these results. CONCLUSIONS: Anticholinergic medication use was associated with poorer performance on measures of cognition, sleep, and mood only in older persons who carried 1 or more ε4 alleles of the APOE gene; this effect did not appear to be the result of an increased risk of cerebrovascular disease.
BACKGROUND: Recent studies found use of anticholinergic medications to be associated with greater performance decrements in older persons who carry an ε4 allele of the apolipoprotein E (APOE) gene than in those carrying only ε2 or ε3 alleles. OBJECTIVES: The present study examined whether the apparently greater behavioral toxicity of anticholinergic drugs in ε4 carriers may result from an increased risk of cerebrovascular disease, which is more common in ε4 carriers. METHODS: Cross-sectional data were available from 240 elderly community volunteers who had participated in 2 different studies of the cognitive and motor effects of normal aging. As part of these studies, information was gathered on subjects' use of anticholinergic medications (based on an inventory of medications taken within 24 hours of testing), risk of cerebrovascular disease (Framingham Stroke Risk Profile), and APOE genotype. Performance data were also available from measures of general cognitive status (Mini-Mental State Examination), executive function (Trail Making Test), mood (Geriatric Depression Scale), sleep (Pittsburgh Sleep Quality Index), and walking speed. Logistic and linear regression models were used to examine how outcomes differed between genotypes and drug use, independent of the risk of cerebrovascular disease. RESULTS: In persons with a non-ε4 genotype, anticholinergic medication use did not significantly affect any of the behavioral measures. By contrast, among ε4 carriers, those taking anticholinergic drugs performed significantly worse than did those not taking such drugs on tests of general cognitive status, executive function, mood, and sleep. Adjusting for participants' stroke risk had a minimal effect on these results. CONCLUSIONS: Anticholinergic medication use was associated with poorer performance on measures of cognition, sleep, and mood only in older persons who carried 1 or more ε4 alleles of the APOE gene; this effect did not appear to be the result of an increased risk of cerebrovascular disease.
Authors: R D Nebes; B G Pollock; C C Meltzer; J A Saxton; P R Houck; E M Halligan; S T DeKosky Journal: Neurology Date: 2005-11-08 Impact factor: 9.910
Authors: Marci L Chew; Benoit H Mulsant; Bruce G Pollock; Mark E Lehman; Andrew Greenspan; Ramy A Mahmoud; Margaret A Kirshner; Denise A Sorisio; Robert R Bies; Georges Gharabawi Journal: J Am Geriatr Soc Date: 2008-05-26 Impact factor: 5.562
Authors: Christian Bocti; Richard H Swartz; Fu-Qiang Gao; Demetrios J Sahlas; Pearl Behl; Sandra E Black Journal: Stroke Date: 2005-09-22 Impact factor: 7.914
Authors: S J Allen; S H MacGowan; S Tyler; G K Wilcock; A G Robertson; P H Holden; S K Smith; D Dawbarn Journal: Neurosci Lett Date: 1997-12-12 Impact factor: 3.046
Authors: Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Ying Cao; Shari M Ling; B Gwen Windham; Tamara B Harris; Joseph T Hanlon; Susan M Rubin; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy Journal: Arch Intern Med Date: 2007-04-23
Authors: Nunzio Pomara; Ken Belzer; Raymundo Hernando; Corazon De La Pena; John J Sidtis Journal: Am J Geriatr Psychiatry Date: 2008-02 Impact factor: 4.105
Authors: Adam P Spira; Yang An; Yu Peng; Mark N Wu; Eleanor M Simonsick; Luigi Ferrucci; Susan M Resnick Journal: Sleep Date: 2017-08-01 Impact factor: 5.849
Authors: Amy Claxton; Laura D Baker; Charles W Wilkinson; Emily H Trittschuh; Darla Chapman; G Stennis Watson; Brenna Cholerton; Stephen R Plymate; Matthew Arbuckle; Suzanne Craft Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: Andrew S P Lim; Lei Yu; Matthew Kowgier; Julie A Schneider; Aron S Buchman; David A Bennett Journal: JAMA Neurol Date: 2013-12 Impact factor: 18.302
Authors: Neelesh K Nadkarni; Subashan Perera; Beth E Snitz; Chester A Mathis; Julie Price; Jeff D Williamson; Steven T DeKosky; William E Klunk; Oscar L Lopez Journal: JAMA Neurol Date: 2017-01-01 Impact factor: 18.302
Authors: Alexandra J Weigand; Mark W Bondi; Kelsey R Thomas; Noll L Campbell; Douglas R Galasko; David P Salmon; Daniel Sewell; James B Brewer; Howard H Feldman; Lisa Delano-Wood Journal: Neurology Date: 2020-09-02 Impact factor: 9.910